Ipsen Investor Resources

Q1 2025 Sales Update

The Q1 2025 sales update have been published on April 16, 2025 at 7H00 and a conference call took place at 14H00 CET.

The latest highlights from Investor Relations

Find out what’s been happening at Ipsen Investor Relations lately – including financial results, announcements, IR events, and more.

12 June 2025

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

28 July 2022

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

26 October 2023

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its…

10 January 2022

J.P. Morgan Healthcare Conference, San Francisco (Management)

Investing for Growth

We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.

Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.

David Loew

Chief Executive Officer

Ipsen in Brief

We are a global biopharmaceutical company with a focus on transformative medicines in our three therapeutic areas of Oncology, Rare Disease and Neuroscience.

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Download Ipsen in Brief

Strong results backed by innovation

With total sales growth of over 9%*, we delivered strong results in 2024, and we’ve had a strong start to 2025. We are on track to build further momentum in our transformation, and to achieve our objectives for the year. *At constant exchange rate.

Download Ipsen’s Annual Report

Investor events

Ipsen is dedicated to providing investors with the tools they need to understand our company and goals. Our events offer investors the opportunity to meet our management and investor-relations teams and learn more about our strategy.

– 01 September 2025

Testing Veeva Video

– 01 September 2025

Testing Vimeo Video

Pipeline

Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across our three therapeutic areas of Oncology, Rare Disease and Neuroscience.

Learn more

Shareholder information

We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.

Learn more

Regulated information

Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.

Learn more